Tweet
Sci Rep
. 2024 Oct 14;14(1):23974.
doi: 10.1038/s41598-024-74502-5. Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing
Huaiya Xie # 1 , Yaqi Wang # 1 , Yan Xu 1 , Luo Wang 1 , Junping Fan 1 , Siqi Pan 1 , Chuan Shi 1 , Xiaoyan Liu 1 , Xiaoxing Gao 1 , Xiaobei Guo 1 , Siyuan Yu 1 , Jia Liu 1 , Dongming Zhang 1 , Yanli Yang 1 , Hong Zhang 1 , Jinglan Wang 1 , Aohua Wu 1 , Xueqi Liu 1 , Jihai Liu 2 , Huadong Zhu 2 , Xiang Zhou 3 , Xinlun Tian 4 5 , Mengzhao Wang 6 7
Affiliations
The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness. This retrospective study included 716 patients who received nirmatrelvir-ritonavir (NR group) or azvudine (FNC group) at Peking Union Medical College Hospital between 1 November 2022 and 27 February 2023. Patients in the FNC group (n = 304) were younger, exhibited less severe symptoms, started antiviral therapy later, received corticosteroids more frequently, and used tocilizumab less frequently than patients in the NR group (n = 412). Within 28 d of therapy, 40 (9.7%) and 20 (6.6%) deaths were in the NR and FNC groups, respectively. No differences were observed between drugs and mortality rates (odds ratio [OR] 0.78, 95% CI 0.40-1.5, P = 0.45), clinical improvement (OR 0.79, 95% CI 0.79-1.3, P = 0.38), and clinical progression (OR 1.0, 95% CI 0.58-1.8, P = 0.96). More patients in the NR group experienced platelet decline than those in the FNC group (17.6% vs. 8.9%, P = 0.034). This study indicated that the effectiveness and safety of azvudine were comparable to those of nirmatrelvir-ritonavir.
Keywords: Azvudine; Coronavirus disease 2019; Mortality; Nirmatrelvir-ritonavir; Seven-category ordinal scale.
. 2024 Oct 14;14(1):23974.
doi: 10.1038/s41598-024-74502-5. Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing
Huaiya Xie # 1 , Yaqi Wang # 1 , Yan Xu 1 , Luo Wang 1 , Junping Fan 1 , Siqi Pan 1 , Chuan Shi 1 , Xiaoyan Liu 1 , Xiaoxing Gao 1 , Xiaobei Guo 1 , Siyuan Yu 1 , Jia Liu 1 , Dongming Zhang 1 , Yanli Yang 1 , Hong Zhang 1 , Jinglan Wang 1 , Aohua Wu 1 , Xueqi Liu 1 , Jihai Liu 2 , Huadong Zhu 2 , Xiang Zhou 3 , Xinlun Tian 4 5 , Mengzhao Wang 6 7
Affiliations
- PMID: 39402091
- DOI: 10.1038/s41598-024-74502-5
The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness. This retrospective study included 716 patients who received nirmatrelvir-ritonavir (NR group) or azvudine (FNC group) at Peking Union Medical College Hospital between 1 November 2022 and 27 February 2023. Patients in the FNC group (n = 304) were younger, exhibited less severe symptoms, started antiviral therapy later, received corticosteroids more frequently, and used tocilizumab less frequently than patients in the NR group (n = 412). Within 28 d of therapy, 40 (9.7%) and 20 (6.6%) deaths were in the NR and FNC groups, respectively. No differences were observed between drugs and mortality rates (odds ratio [OR] 0.78, 95% CI 0.40-1.5, P = 0.45), clinical improvement (OR 0.79, 95% CI 0.79-1.3, P = 0.38), and clinical progression (OR 1.0, 95% CI 0.58-1.8, P = 0.96). More patients in the NR group experienced platelet decline than those in the FNC group (17.6% vs. 8.9%, P = 0.034). This study indicated that the effectiveness and safety of azvudine were comparable to those of nirmatrelvir-ritonavir.
Keywords: Azvudine; Coronavirus disease 2019; Mortality; Nirmatrelvir-ritonavir; Seven-category ordinal scale.